Accretion Pharmaceuticals Limited

14 May 2025 - 16 May 2025 Individual Category SME NSE

Min Investment

₹121200

Price Band

₹96-₹101

Issue Size

27.35 lakhs
Equity Shares

Lot Size

1200

IPO Dates
img

14 May 2025

Open Date

img

16 May 2025

Close Date

img

19 May 2025

Allotment Date

img

21 May 2025

Listing Date

Accretion Pharmaceuticals IPO open date is May 14, 2025, and the closing date is May 16, 2025. This new IPO is a book-built price issue. This upcoming IPO is offering entirely fresh issues of up to 29,46,000 equity shares. Accretion Pharmaceuticals IPO issue price band is Rs 96 to Rs 101 per share. As of now, the live GMP of the Accretion Pharmaceuticals IPO is at 0, indicating neutral sentiment and low interest among investors for this IPO. Accretion Pharmaceuticals IPO lot size is 1,200 shares, and the allotment status will be finalised on Monday, May 19, 2025. The minimum investment for retail investors is Rs 1,21,200. The registrar for the Accretion Pharmaceuticals IPO is Kfin Technologies Limited. The listing date is Wednesday, May 21, 2025.

Know Before Investing

Strengths icon

  • Well-established relationships with clients and suppliers.
  • Committed to producing high-quality pharmaceutical products.
  • Certified for both quality and environmental management systems.

Weaknesses icon

  • Involvement in legal and regulatory proceedings may pose risks.
  • Faces a high compliance load in global markets.
  • Operations rely on a single manufacturing unit.

About Accretion Pharmaceuticals Limited

Accretion Pharmaceuticals Limited, established in 2012 in Ahmedabad, Gujarat, began as a partnership with a vision to deliver healthcare products of international quality at competitive prices. In 2023, the company transitioned into a limited entity, marking a significant milestone in its growth journey. Today, Accretion is a conglomerate comprising four robust companies and a dedicated team of over 400 professionals. The company’s WHO-cGMP and GLP-certified manufacturing facilities enable the production of a diverse portfolio, including tablets, capsules, oral liquids, topical preparations, and oral powders. Accretion operates in more than 30 countries, continually expanding its global footprint while upholding its core philosophy of “Growing Together”-fostering collaborative relationships with employees, customers, and partners. Driven by a commitment to quality, innovation, and accessibility, Accretion Pharmaceuticals Limited aims to empower healthier lives and shape the future of healthcare with a focus on Ayurveda, nutraceuticals, and pharmaceutical solutions.

Founded

2012

Managing Director

Vivek Ashok Kumar Patel

Parent Organization

IPO Objectives

Accretion Pharmaceuticals IPO objectives include utilising the funding received from the fresh issue or capital expenditure on the purchase of new equipment and machinery, as well as for upgrading its existing manufacturing facility. Additionally, funds will be allocated for repayment/prepayment of certain borrowings, meeting working capital requirements, and addressing general corporate purposes.

Company Promoters

Mr. Mayur Popatlal Sojitra

Mr. Harshad Nanubhai Rathod

Mr. Vivek Ashok Kumar Patel

Mr. Hardik Mukundbhai Prajapati

Subscription Details

Investor Category Subscription (times)
Qualified Institutions 0
Non-Institutional Buyers 0
bNII (bids above ₹10L) 0
sNII (bids below ₹10L) 0
Retail Investors 0
Employees 0
Others 0
Total 0

How to Apply for IPO

img img

Login

Login to your Bigul Account

Select Lots & Price

Choose the number of lots and price

UPI ID

Enter your UPI ID

UPI Mandate Request

A UPI Mandate Request Triggered

Approve Mandate

Approve the UPI Mandate Request

IPO Allotment

YES Share will be credited. and the amount will be debited

Close

Let's Open Free Demat Account